At 17.9% CAGR, the North America Antibody Drug Conjugates Market is Projected to be Worth US$ 13,681.58 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the North America antibody drug conjugates market was valued at US$ 3,659.81 million in 2022 and is expected to reach US$ 13,681.58 million by 2030, registering a CAGR of 17.9% from 2022 to 2030. Growing strategic partnerships to develop antibody drug conjugates and rising incidences of cancer are among the critical factors attributed to the North America antibody drug conjugates market expansion.

Antibody-drug conjugates (ADCs) have received significant attention worldwide for cancer therapy. Since the approval of Mylotarg (Pfizer, Inc's first ADC) by the US Food and Drug Administration (FDA) in 2000, there has been substantial growth in strategic decisions by pharmaceutical leaders despite the COVID-19 pandemic. In 2020, various pharmaceutical companies entered into partnerships to develop ADCs. For instance, in July 2020, AstraZeneca and Daiichi Sankyo collaborated to develop and commercialize DS-1062. DS-1602 is Daiichi Sankyos proprietary trophoblast cell-surface antigen 2 (TROP2)-directed ADC to treat multiple tumor types.

Likewise, in December 2022, Merck & Co., Inc. (MSD) and Kelun-Biotech, a Sichuan Kelun Pharmaceutical Co., Ltd. subsidiary, partnered to develop seven investigational preclinical ADCs to treat cancer. Under the agreement, MSD received a grant for exclusive global licenses from Kelun Biotech to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies. In addition, MSD has exclusive options to obtain additional licenses for ADC candidates.

Similarly, in April 2023, BioNTech SE and Duality Biologics (Suzhou) Co. Ltd signed a strategic partnership agreement to develop next-generation ADCs to treat cancer and autoimmune diseases. Under the partnership agreement, BioNTech SE will have access to DualityBios lead candidate, DB-1303. DB-1303 is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2 (HER2). HER2 is an overexpressed common target in most cancer types and contributes to cancer cells aggressive growth and spread. Secondly, BioNTech SE will have access to another topoisomerase-1 inhibitor-based ADC candidate, DB-1311. Companies have aimed to transform and commercialize innovative therapies worldwide.

On the contrary, high cost of ADCs development and commercialization hampers the growth North America antibody drug conjugates market.

Based on technology, the North America antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held 69.8% share of the North America antibody drug conjugates market in 2022, amassing US$ 2,553.86 million. It is projected to garner US$ 9,427.84 million by 2030 to expand at 17.7% CAGR during 2022-2030.

Based on application, the North America antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held 53.6% share of the North America antibody drug conjugates market in 2022, amassing US$ 1,960.06 million. It is projected to garner US$ 7,551.09 million by 2030 to expand at 18.4% CAGR during 2022-2030.

Based on distribution channel, the North America antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 66.2% share of North America antibody drug conjugates market in 2022, amassing US$ 2,421.99 million. It is projected to garner US$ 9,280.83 million by 2030 to expand at 18.3% CAGR during 2022-2030.

Based on country, the North America antibody drug conjugates market is categorized into US, Canada, and Mexico. The US held 86.6% share of North America antibody drug conjugates market in 2022, amassing US$ 3,167.57 million. It is projected to garner US$ 12,162.92 million by 2030 to expand at 18.3% CAGR during 2022-2030.

Key players operating in the North America antibody drug conjugates market are ADC Therapeutics SA, Pfizer Inc, Hoffmann-La Roche Ltd, ImmunoGen, Inc, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd, among others.

- In Mar 2023, Pfizer Inc. and Seagen Inc entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.

- In Sept 2023, Seagen Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagens world-class expertise and knowledge of ADC development, manufacturing, and commercialization to maximize the potential of disitamab vedotin.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com